Emergent BioSolutions target raised to $35 from $27 at JP Morgan

theflyonthewall.com

JP Morgan raised its price target for Emergent BioSolutions after the U.S. government issued an RFP for a 5-year procurement contract for the company’s anthrax vaccine BioThrax. The firm reiterates an Overweight rating on the stock.

View Comments (0)